{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RSV+Vaccine&page=3",
    "query": {
      "intervention": "RSV Vaccine",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 143,
    "total_pages": 15,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RSV+Vaccine&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RSV+Vaccine&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T13:06:59.121Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03227029",
      "title": "Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSV ΔNS2/Δ1313/I1314L",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV 276",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "24 Months",
        "sex": "ALL",
        "summary": "6 Months to 24 Months"
      },
      "enrollment_count": 65,
      "start_date": "2017-09-22",
      "completion_date": "2020-10-01",
      "has_results": true,
      "last_update_posted_date": "2022-04-22",
      "last_synced_at": "2026-10-19T13:06:59.121Z",
      "location_count": 12,
      "location_summary": "La Jolla, California • Los Angeles, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03227029"
    },
    {
      "nct_id": "NCT04798001",
      "title": "Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Meissa Vaccines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 130,
      "start_date": "2021-04-12",
      "completion_date": "2022-10-31",
      "has_results": false,
      "last_update_posted_date": "2022-08-02",
      "last_synced_at": "2026-10-19T13:06:59.121Z",
      "location_count": 2,
      "location_summary": "Lenexa, Kansas • Raleigh, North Carolina",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04798001"
    },
    {
      "nct_id": "NCT05639894",
      "title": "Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Immunization"
      ],
      "interventions": [
        {
          "name": "RSV vaccine candidate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 865,
      "start_date": "2022-11-17",
      "completion_date": "2025-05-02",
      "has_results": true,
      "last_update_posted_date": "2026-08-05",
      "last_synced_at": "2026-10-19T13:06:59.121Z",
      "location_count": 25,
      "location_summary": "Huntsville, Alabama • Mesa, Arizona • Peoria, Arizona + 22 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05639894"
    },
    {
      "nct_id": "NCT03916185",
      "title": "Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus (RSV)"
      ],
      "interventions": [
        {
          "name": "RSV ΔNS2/Δ1313/I1314L Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV 6120/ΔNS2/1030s Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV 276 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "25 Months",
        "sex": "ALL",
        "summary": "6 Months to 25 Months"
      },
      "enrollment_count": 67,
      "start_date": "2019-06-20",
      "completion_date": "2024-04-25",
      "has_results": true,
      "last_update_posted_date": "2025-02-21",
      "last_synced_at": "2026-10-19T13:06:59.121Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • San Diego, California • Aurora, Colorado + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03916185"
    },
    {
      "nct_id": "NCT06866405",
      "title": "A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "RSV Infection"
      ],
      "interventions": [
        {
          "name": "RSVpreF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "0 Years and older"
      },
      "enrollment_count": 550,
      "start_date": "2025-04-16",
      "completion_date": "2028-02-24",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-10-19T13:06:59.121Z",
      "location_count": 81,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06866405"
    },
    {
      "nct_id": "NCT05559476",
      "title": "A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSVPreF3 OA investigational vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "FLU HD vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 1029,
      "start_date": "2022-10-20",
      "completion_date": "2023-08-15",
      "has_results": true,
      "last_update_posted_date": "2024-09-24",
      "last_synced_at": "2026-10-19T13:06:59.121Z",
      "location_count": 46,
      "location_summary": "Birmingham, Alabama • Tempe, Arizona • Canoga Park, California + 41 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05559476"
    },
    {
      "nct_id": "NCT03049488",
      "title": "Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Respiratory Syncytial Virus"
      ],
      "interventions": [
        {
          "name": "VRC-RSVRGP084-00-VP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aluminum Hydroxide Suspension",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 95,
      "start_date": "2017-02-22",
      "completion_date": "2019-10-03",
      "has_results": true,
      "last_update_posted_date": "2020-10-23",
      "last_synced_at": "2026-10-19T13:06:59.121Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03049488"
    },
    {
      "nct_id": "NCT05330975",
      "title": "A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1345",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Afluria® Quadrivalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.214",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 3317,
      "start_date": "2022-04-01",
      "completion_date": "2024-11-08",
      "has_results": true,
      "last_update_posted_date": "2025-12-30",
      "last_synced_at": "2026-10-19T13:06:59.121Z",
      "location_count": 62,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Garden Grove, California + 51 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05330975"
    },
    {
      "nct_id": "NCT05879107",
      "title": "Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSVPreF3 OA investigational vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PCV20",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 1113,
      "start_date": "2023-05-26",
      "completion_date": "2024-05-07",
      "has_results": true,
      "last_update_posted_date": "2025-05-18",
      "last_synced_at": "2026-10-19T13:06:59.121Z",
      "location_count": 20,
      "location_summary": "Guntersville, Alabama • Phoenix, Arizona • Huntington Beach, California + 17 more",
      "locations": [
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Modesto",
          "state": "California"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05879107"
    },
    {
      "nct_id": "NCT04605159",
      "title": "A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSV MAT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 11194,
      "start_date": "2020-11-20",
      "completion_date": "2023-06-14",
      "has_results": true,
      "last_update_posted_date": "2025-02-20",
      "last_synced_at": "2026-10-19T13:06:59.121Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04605159"
    }
  ]
}